Marketed under the name of Imvanex in Europe, from Jynneos in the United States and Imvamune in Canada, it is a vaccine of third generation (does not replicate in the human body) authorized in Europe since 2013 and indicated against smallpox in adults.
The European medicines regulator (EMA) announced in early June that it had started talks with Bavarian Nordic to eventually extend its use against monkeypox.
Monkeypox, which is not usually fatal, can cause fever, headache, muscle aches, back pain, swollen lymph nodes, chills, and fatigue.
Rashes (on the face, palms of the hands, soles of the feet), lesions, pustules, and finally scabs then appear. Your symptoms They usually disappear after two or three weeks.
According to the World Health Organization (WHO), as of June 8, the number of confirmed cases of the disease was 1,300 in the world in non-endemic countries, although monkeypox is endemic in 11 countries in West Africa and in Africa. central.
Third confirmed case in Argentina
monkeypox.jpg
The Ministry of Health confirmed this Saturday the third case of monkeypox in the country, in a 36-year-old resident of the City of Buenos Aires. It is the first without travel history in the country, according to the national portfolio.
The INEI-ANLIS Malbrán National Reference Laboratory confirmed on June 9 the first case of monkeypox with no history of travel in Argentina in a 36 year old man resident in CABA who “is in good health, fulfilling the corresponding isolation and hospitalized for his care”.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
